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Tissue Distribution of 18F-FDG-Labeled Peripheral
Hematopoietic Stem Cells After Intracoronary
Administration in Patients with Myocardial
Infarction
Won Jun Kang1, Hyun-Jae Kang2, Hyo-Soo Kim2, June-Key Chung1, Myung Chul Lee1, and Dong Soo Lee1
1Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea; and 2Department of Internal Medicine,
Seoul National University College of Medicine, Seoul, Korea
Adult stem cell therapy is expected to improve left ventricular
function in patients with myocardial infarction. Because of the
low risk of arrhythmia and the maximal concentration at the tar-
get tissue, intracoronary infusion of stem cells is preferred. The
aim of this study was to investigate the homing and tissue distri-
bution of intracoronary injected peripheral hematopoietic stem
cells labeled with 18F-FDG. Methods: Seventeen patients with
myocardial infarction were included as the intracoronary injec-
tion group (14 males, 3 females; age, 58 6 12 y). Three patients
underwent intravenous stem cell injection as the intravenous
injection group (3 males, 0 females; age, 506 20 y). After mobi-
lization with granulocyte colony-stimulating factor (G-CSF),
peripheral stem cells were collected by means of apheresis.
18F-FDG labeling of stem cells was performed for 40 min with
gentle intermittent mixing at 37C. The mean labeling efficiency
was 72% (range, 46%–95%), and 44.4–175 MBq (1.2–5 mCi) of
18F-FDG-labeled stem cells were injected via an intracoronary
catheter after stenting in infarct-related arteries. PET/CT images
were obtained with a 3-dimensional acquisition mode 2 h after
intracoronary infusion.Results: Two hours after intracoronary in-
fusion, 1.5% (range, 0.2%–3.3%) of injected stem cells accumu-
lated at the infarcted myocardium. Outside of the myocardium,
spleen, liver, bladder, and bone marrow showed a high stem
cell accumulation. The delayed image of a patient up to 20 h
showed a prolonged residence of stem cells at the myocardium.
Intravenous injection of stem cells showed a high initial lung up-
take with no myocardial activity. Conclusion: We have shown
that 18F-FDG-labeled stem cell PET could be used to assess
the tissue distribution and to measure the amount of stem cells
at a target tissue. 18F-FDG-labeled stem cell PET can be used
to measure and optimize the amount of stem cells injected.
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Autologous bone marrow stem cell transplantation,
using stem cells aspirated from the bone marrow, has been
reported to improve myocardial perfusion and cardiac
function (1–4). However, peripheral stem cell therapy is a
more acceptable method considering its noninvasiveness.
Recently, it has been reported that peripheral stem cell
therapy could improve cardiac function in patients with
myocardial infarction (5).
With regard to the route of administration, intracoronary
infusion of stem cells might have an advantage over intra-
venous injection because of possible maximal delivery to the
infarcted myocardium during the first passage of injected
stem cells. Furthermore, compared with direct myocardial
injection, intracoronary infusion has a low risk of arrhythmia.
Because of the high concentration at the target tissue and the
low risk of arrhythmia, intracoronary infusion of stem cells
was preferred in later studies (2,5,6). Coronary flowblockade
after stem cell injection is expected tomake stem cells adhere
to the myocardial capillaries and to promote cellular migra-
tion into the infarcted zone (7).
To evaluate the effect of stem cell therapy, assessments
of stem cell homing, distribution, and differentiation are
crucial. Despite recent advances in molecular imaging tech-
niques, stem cell tracking using genetically modified cells
is still limited in human subjects because of the possible
hazard of genetic modification, though unproven. Cell la-
beling using a radioisotope is an established method in
clinical nuclear medicine and has minimal toxicity. Several
studies already reported that indium- or technetium-labeled
stem cell imaging could be used to monitor the fate of
transplanted stem cells (8,9).
PET is an ideal imaging method for stem cell tracking
because of its high spatial resolution and high sensitivity.
Furthermore, because glucose uptake is a physiologic process,
Received Feb. 19, 2006; revision accepted Apr. 26, 2006.
For correspondence or reprints contact either of the following:
Dong Soo Lee, MD, PhD, Department of Nuclear Medicine, Seoul National
University College of Medicine, 28 Yeongeon-dong, Jongno-gu, Seoul 110-
744, Korea.
E-mail: dsl@plaza.snu.ac.kr
June-Key Chung, MD, PhD, Department of Nuclear Medicine, Seoul
National University College of Medicine, 28 Yeongeon-dong, Jongno-gu,
Seoul 110-744, Korea.
E-mail: jkchung@plaza.snu.ac.kr
COPYRIGHT ª 2006 by the Society of Nuclear Medicine, Inc.
PERIPHERAL STEM CELL INFUSION IN MYOCARDIUM • Kang et al. 1295
by Yonsei University - Medical Library on June 16, 2014. For personal use only. jnm.snmjournals.org Downloaded from 
18F-FDG uptake by stem cells does not require any cellular
modification and will occur in vitro in the same manner as
in vivo without specific manipulation except for fasting the
cells (10,11). Recent preliminary studies indicated that
bone marrow stem cells labeled with 18F-FDG could be
used to monitor cell homing into the myocardium (11,12).
So far, however, the distribution of peripheral stem cells
after intracoronary injection has not been elucidated and
the usefulness of delayed 18F-FDG PET for the study has
not been established. The aim of this study was to evaluate
the homing, distribution, and delayed distribution of pe-
ripheral stem cells after intracoronary injection of these
cells using 18F-FDG-labeled stem cell PET.
MATERIALS AND METHODS
Subjects
We enrolled 17 patients (14 males, 3 females; age, 58 6 12 y)
with an ST-elevated myocardial infarction who were scheduled to
undergo elective percutaneous coronary intervention (PCI) and
stent implantation at the infarct-related artery. Eleven patients had
a history of acute chest pain (,13 d), and 5 had a history of an old
myocardial infarction (.90 d) (Table 1).
To evaluate the distribution of intravenously injected stem cells, 3
additional patients with acute myocardial infarction were enrolled
as the intravenous injection group (3 males, 0 females; age, 50 6
20 y). The patients in the intravenous injection group also under-
went PCI and stent implantation before stem cell injection.
Peripheral Stem Cell Preparation
After successful PCI and stent implantation, granulocyte colony-
stimulating factor (G-CSF; Dong-A Pharmaceuticals) was subcuta-
neously injected at 10 mg/kg body weight for 4 d. Peripheral blood
stem cells were obtained using a COBE spectra apheresis system
(COBE BCT Inc.) with the mononuclear cell collection method
recommended by the manufacturer. Stem cell collection was
performed over 60–90 min with an antecubital vein access proce-
dure. The total processing volume of blood ranged from 4,500 to
7,000 mL, and 30–45 mL of apheresis fluid were obtained.
18F-FDG Labeling
A total of 2 mL of apheresis fluid containing ethylenediami-
netetraacetic acid (EDTA) as the anticoagulation agent was used
for 18F-FDG labeling. Red-blood-cell hemolysis over 30 s was
TABLE 1
Patient Characteristics and Percent Activity per Injected Dose at Myocardium
Case
Age
(y) Sex Route Territory
Time from
infarction (d)
CK
(IU/mL)
CK-MB
(ng/mL)
Injection
dose (MBq)
Activity at
myocardium (%)
1 65 M IC LAD 153 85 2.5 111.0 2.1
2 30 M IC RCA 5 477 7.5 111.0 2.7
3 58 M IC LAD 12 100 1.7 77.7 1.1
4 62 M IC LAD 7 114 3.1 148.0 3.3
5 59 M IC LAD 92 96 22 74.0 2.0
6 54 M IC LAD 8 847 57 37.0 0.5
7 71 M IC LAD 105 94 1.9 148.0 1.3
8 44 M IC LAD 3 1,611 242 148.0 1.0
9 71 M IC LAD 10 127 25 103.6 0.8
10 62 M IC LAD .300 84 6 99.9 0.2
11 43 M IC RCA 12 862 71.1 107.3 1.1
12 69 F IC LAD 6 5,027 279 355.2 1.3
13 43 M IC LAD 6 1,163 154 114.7 1.4
14 70 F IC LAD 5 1,165 204 125.8 1.4
15 64 M IC LAD 202 148 2.3 136.9 2.4
16 67 F IC LCX 40 97 4.2 155.4 1.4
17 56 M IC RCA 12 1,307 136.5 118.4 1.8
18 39 M IV LAD 7 702 81.5 177.6 —
19 74 M IV LAD 7 105 1.9 170.2 —
20 39 M IV RCA 7 3,004 200.5 214.6 —
CK 5 creatine kinase; CK-MB 5 creatine kinase isoenzyme containing M and B subunits; IC 5 intracoronary injection; LAD 5 left
anterior descending artery; RCA 5 right coronary artery; LCX 5 left circumflex artery; IV 5 intravenous injection.
FIGURE 1. Trypan blue staining of 18F-FDG-labeled stem
cells. There were few trypan blue–defective cells.
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done with 30 mL of distilled water. After 5 min of centrifugation
at 1,800 rpm, the pellet containing stem cells was obtained. A total
of 175–370 MBq (5–10 mCi) of 18F-FDG in 1 mL of normal
saline was mixed with the pellet. Stem cells in this 18F-FDG
solution were incubated for 40 min at 37C with gentle swirling at
5-min intervals. Labeled stem cells were resuspended in 20 mL of
normal saline and then centrifuged for 5 min at 1,800 rpm. The
labeling efficiency was measured by counting the radioactivity in
the pellet and the supernatant. This pellet was resuspended in
1 mL of normal saline and administered immediately by intra-
coronary injection to the patients. Sixty minutes were required for
stem cell labeling procedures.
To examine the stability of 18F-FDG binding, the pellet was
incubated with plasma for 3 h. The labeling efficiency after incu-
bation was also measured by counting the radioactivity in the pellet
after centrifugation.
For the viability test, labeled stem cells suspended in plasma
were stored for 3 h. Cell viability was assessed by trypan blue
staining.
Stem Cell Administration and PET/CT Image Acquisition
In the coronary infusion group, 18F-FDG-labeled peripheral
stem cells were administered by over-the-wire angioplasty balloon
catheter through another coronary catheterization performed 4–5 d
after initial PCI. Restoration of TIMI (Thrombolysis in Myocar-
dial Infarction) grade 3 flow and preserved coronary flow reserve
measured by coronary Doppler wire were confirmed before stem
cell infusion.
In the intravenous injection group, 18F-FDG-labeled stem cells
prepared with the same protocol were injected in bolus via a pe-
ripheral vein at 4–5 d after PCI.
After 2 h of stem cell injection, whole-body PET images were
acquired with the conventional 3-dimensional protocol of 18F-
FDG PET using a Gemini PET/CT camera (Philips). Low-dose CT
(120 kV, 50 mA) from head to pelvis was acquired for attenuation
correction and anatomic localization. Emission PET images were
acquired for 2 min 30 s per each bed with a 3-dimensional ac-
quisition mode.
To examine the delayed distribution, an additional 4-h image
was acquired in 2 patients and 4- and 20-h images were acquired
in another patient.
Dosimetry
Transaxial images from 2- and 4-h acquisitions of a patient
were analyzed. A region of interest was drawn manually on
FIGURE 2. PET/CT images of 65-y-old man with history of
anterior wall infarction. After percutaneous intervention, 18F-
FDG-labeled stem cells were injected via intracoronary cathe-
ter. PET/CT images were obtained 2 h after injection. Stem cell
accumulation at myocardium is well visualized (arrow). Total
amount of stem cells at myocardium was 2.1% of injected dose
(case 1 of Table 1).
FIGURE 3. PET/CT image of 30-y-old man with inferior wall
infarction (case 2 of Table 1). Total amount of stem cells at
myocardium (arrow) was 2.7% of injected dose.
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transaxial images on the bone marrow, myocardium, liver, spleen,
and bladder. The half-life and residence time were calculated
for each organ from the time–activity curves of these organs.
MIRDOSE3.1 was used to calculate radiation exposure (Oak
Ridge Associated University, Oak Ridge, TN).
RESULTS
Stem Cell Labeling with 18F-FDG
Two milliliters of apheresis fluid rich in mononuclear
cells were used for 18F-FDG labeling. The mononuclear
cell fraction was 84.3% and the remaining cells were
primarily neutrophils and their precursor cells. An initial
experiment indicated that the best labeling efficiency was
acquired with an EDTA-containing sample. The same sam-
ples from 1 patient showed different labeling efficiencies:
96% in EDTA, 62% in heparin, and 56% in acid–citrate–
dextrose (ACD). Therefore, subsequent samples were treated
with EDTA for anticoagulation.
The overall labeling efficiency was 73% 6 17% with
EDTA. Finally, 136.9 6 64.8 MBq (3.7 6 1.75 mCi) of
18F-FDG-labeled stem cells were prepared. The injected
activity of stem cells is presented in Table 1. The heparin-
containing sample frequently showed cell aggregation and
caused labeling failure. ACD also showed a low labeling ef-
ficiency, which was thought to be related to the glucose
contained in ACD.
Stability and Viability Test
18F-FDG-labeled stem cells were incubated in plasma for
3 h and resuspended with normal saline. The radioactivity
of the stem cell-containing pellet was $90%.
For viability assessment, microscopic examination was
done on 18F-FDG-labeled stem cells after 3 h of incubation
in plasma. Microscopic examination revealed that there
were few trypan blue–defective stem cells (Fig. 1).
Distribution of Stem Cells After Intracoronary Injection
18F-FDG-labeled stem cell PET images were acquired in
17 patients in the intracoronary injection group and in 3 in
the intravenous injection group without complication dur-
ing the injection period (Table 1). A total of 4.5 · 108
leukocytes (8.3% 6 10.2% CD341 cells) labeled with 18F-
FDG was injected.
PET images were acquired after 2 h of stem cell injec-
tion. 18F-FDG-labeled stem cells showed physiologic dis-
tribution predominantly within the reticuloendothelial system
(Figs. 2 and 3). Liver, spleen, and bone marrow showed
prominent stem cell uptake. Brain and bladder activity of
stem cell imaging were markedly lower than that of the
pure 18F-FDG PET image (Table 2).
There was no significant difference in the stem cell
amount at the myocardium according to the age of in-
farction (1.6 6 0.88 vs.1.48 6 0.79; P 5 0.78, in acute
myocardial infarction and old myocardial infarction, re-
spectively).
No correlation was found between the CK-MB (creatine
kinase isoenzyme containing M and B subunits) level and
stem cell activity at the myocardium (P 5 0.372).
Stem Cell Quantification at Myocardium and Changes in
Delayed Periods
Stem cell activity was found on myocardium within the
territories of infarct-related arteries injected. The calculated
amount on myocardium was 1.5% 6 0.8% of injected dose.
It ranged from 0.2% to 3.3%. To evaluate the change of tis-
sue distribution and homing at the myocardium, 4-h and
20-h delayed images were acquired in 2 subjects and 1 subject,
respectively (Tables 3 and 4). Myocardial uptake persisted
until 4-h delayed images and even remained until 20-h
delayed images (Figs. 4A and 4B).
TABLE 3
Distribution of Intracoronary Injected Stem Cells Measured
at 2 and 4 Hours After Injection
Activity of injected stem cells (%)
Organ 2 h 4 h
Myocardium 1.12 1.1
Liver 23.6 19.3
Spleen 12.3 12.8
Case 3, Figure 4A.
TABLE 2
Percent Activity of Intracoronary Injected Stem Cells at 2
Hours After Injection
Organ Uptake (%)
Liver 8
Lung ,0.5
Spleen 15.7
Brain 5.78
Bladder 6.1
Myocardium 2.1
Case 1, Figure 2A.
TABLE 4
Distribution of Intracoronary Injected Stem Cells Measured
at 2 and 20 Hours
Activity of injected stem cells (%)
Organ 2 h 20 h
Myocardium 3.27 1.49
Liver 17.2 16.6
Spleen 6.98 2.4
Case 4, Figure 4B.
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Distribution of Stem Cells After Intravenous Injection
After intravenous injection of 18F-FDG-labeled stem
cells, there was no stem cell activity within the myocar-
dium. The whole-body distribution of stem cells after in-
travenous injection was similar to that of intracoronary
injection except for the initial high lung uptake (Table 5).
The reticuloendothelial system took up most of the stem
cells after intravenous injection. Initial high lung uptake on
the 30-min image was cleared away and splenic uptake
increased on the 2-h delayed image (Fig. 5).
Dosimetry
Similar to white blood cell images, 18F-FDG-labeled
stem cell uptake occurred primarily in the reticuloendo-
thelial system. The radiation dose to the myocardium
was calculated to be 0.017 mGy/MBq (0.064 rad/mCi)
(Table 6).
DISCUSSION
This study demonstrated that 18F-FDG-labeled stem cell
PET was feasible to assess stem cell homing and distribu-
tion. Stem cell imaging with PET could evaluate the
amount of stem cells at the myocardium quantitatively and
might be used to assess the adequacy of stem cell injection
to the target tissue.
We successfully labeled peripheral stem cells supplied
by apheresis with 18F-FDG. Among the different labeling
methods available in nuclear medicine, 18F-FDG labeling
and imaging with PET had the advantages of high resolu-
tion, adequate attenuation correction, and easy accessibil-
ity. Stem cells physiologically take up 18F-FDG at adequate
temperature and 18F-FDG concentration, resulting in the
high labeling efficiency reported in this study. The only
requirement was the fasting of the stem cells. Stem cells
were believed to undergo minimal damage during the
labeling procedures and could preserve migration or pro-
liferation ability. Trypan blue staining showed that stem
cell viability was preserved in plasma even 1 h after 18F-
FDG labeling. Because only viable cells could contain 18F-
FDG in its cytoplasm, the amount of 18F-FDG-labeled cells
might mean the viability of the cells. Because of these
theoretic advantages, in vivo imaging with 18F-FDG label-
ing of stem cells was already recommended to track stem
cells in animal and human studies (12,13).
Selective intracoronay injection was thought to deliver a
maximum concentration of cells homogenously to the
injured myocardium during the cells’ first passage. This
belief was confirmed on 18F-FDG-labeled stem cell PET.
The amount of stem cells retained at the myocardium after
intracoronary injection was 1.5% on average 2 h after in-
jection in this study. This result is consistent with the
amount of bone marrow stem cells injected by the intra-
coronary route but collected directly by the bone marrow
aspiration (12). We demonstrated that intracoronary in-
jected peripheral stem cells also showed substantial homing
at the myocardium. Now, the size of stem cells, acquisition
time after injection, and method of injection may affect the
results, and further comparison studies are needed to
determine which cell types are homing better at the target
tissue.
FIGURE 4. Distribution of stem cells after intracoronary
injection at 24 h (A, case 3 of Table 1) and at 2–20 h (B, case
4 of Table 1). Stem cell activity (arrow) remained on 4-h image,
and splenic uptake was prominent. Myocardial uptake could be
noted on CT-guided anatomic localization on 20-h image.
TABLE 5
Distribution of Intravenously Injected Stem Cells Measured
at 2 and 4 Hours
Activity of injected stem cells (%)
Organ 2 h 4 h
Myocardium — —
Liver 22.0 21.3
Spleen 14.8 42.12
Lung 19.1 5.8
Case 18, Figure 5.
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The empiric dose of autologous bone marrow to achieve
the therapeutic effect was 10–40 · 106 cells in human
studies (13). Considering the various sizes of the infracted
myocardium and the variable amount of resident stem cells
after intracoronary injection, further studies are, of course,
warranted to determine the optimal dose of stem cells.
Quantification of stem cells at target tissue will be a pre-
requisite to assess the actual dose of stem cells at the target
tissue and to establish an optimal procedure of stem cell
therapy. For this purpose, 18F-FDG-labeled stem cell PET
has the advantages of high sensitivity and established quan-
tification methodology.
We acquired a 20-h delay image with the 3D acquisition
method to determine whether stem cells would remain at
damaged myocardium for a substantial time. Because of the
short half-life of 18F, counts for the 20-h delayed image
quality were not as good as those of 4-h image. However,
with the help of CT-guided localization, we could identify
remaining stem cell activity at the injured myocardium
(Fig. 4). Because of the poor quality and short half-life of
18F-FDG, the 20-h image should not be a routine procedure
for evaluating stem cell distribution.
Radiation exposure by 18F-FDG-labeled stem cell imaging
might be another obstacle for a routine use of stem cell
tracking methods. The radiation dose of 18F-FDG PET calcu-
lated in this studywas similar to that of 18F-FDG-labeledwhite
blood cell imaging (14). As high radiation exposure to stem
cells may cause functional impairment, the imaging method
with a minimal dose to stem cells is necessary. Although
functional evaluation of stem cells after 18F-FDG labelingwas
not performed in this study, radiation exposure to stem cells
was thought to be permissive according to our dosimetry
results compared with indium or technetium labeling.
Intravenously injected stem cells showed high lung
uptake on the initial 30-min image and rapid clearance
after 2 h. Splenic uptake markedly increased on the 4-h
delayed image. As was expected, the amount of stem cells
at the myocardium was minimal in the intravenous injec-
tion group, and PET images of the myocardium yielded
almost the background activity. Initial high lung uptake
indicates that intravenous injection of stem cells might
represent impediments of these cells in their lung passage.
Considering this fact, intravenous injection of stem cells
may be an inappropriate method because of the very low
concentration of stem cells, if any, at the target tissue.
Although coronary vessel patency was confirmed by
angiography before stem cell infusion, several patients
showed minimal delivery of stem cells in injured myocar-
dium. The age, acute or chronic status, vascular resistance
after PCI, and adequacy of infusion procedure might in-
fluence the amount of stem cells at the myocardium. The
degree of functional improvement after stem cell therapy is
expected to have a correlation with the amount of stem cells
at the myocardium, and further study is underway.
FIGURE 5. PET/CT images of 39-y-old
male patient with anterior wall infarction
(case 18 of Table 1). Stem cells were
injected intravenously, and PET/CT im-
ages were acquired at 30 min (A) and at
2 h (B). Initial high lung uptake was
observed at 30 min and cleared on 2-h
image. No myocardial uptake was evi-
dent on both images.
TABLE 6
Radiation Dose of Intracoronary Injected 18F-FDG-Labeled
Stem Cells
Organ Radiation dose*
Myocardium 0.0173 (0.0641)
Bone marrow 0.0433 (0.0117)
Bladder 0.0631 (0.0171)
Liver 0.148 (0.547)
Spleen 0.708 (2.62)
*Radiation dose is expressed in mGy/Bq (rad/mCi).
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111In-Indium oxine or 99mTc-hexamethylpropyleneamine
oxime (99mTc-HMPAO) has been widely accepted as an in
vivo cell-tracking method. Hematopoetic stem cells and
mesenchymal stem cells were successfully labeled with
indium oxine or 99mTc-HMPAO in animal studies (8,9,
15,16). Although indium oxine imaging has the advantage
of delayed imaging because of its longer half-life, poor
resolution and higher radiation exposure might limit human
application.
CONCLUSION
Stem cell PET with the 18F-FDG labeling method is
feasible in human subjects with minimal risk. 18F-FDG-
labeled stem cell imaging could be used to evaluate stem
cell homing and distribution during the early phase in
patients who undergo stem cell therapy. Information on
stem cell homing and distribution in human trials might be
used to predict the effect of stem cell therapy in terms of
optimal stem cell dose calculation and development of
adequate administration methods.
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